anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will consist of two phases, plus a screening period. During the screening period, subject eligibility for the study will be determined. During Phase 1, qualified participants will be randomly assigned to one of two elimination diet therapies--the 1FED or the 4FED. Participants will remain on the assigned dietary therapy for 12 weeks. At the end of 12 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status. Participants whose EoE is in remission (i.e. \<15 eos/hpf) will be done with the study.

Participants whose EoE is still active (i.e. ≥15 eos/hpf) will continue into Phase 2 of the study. During Phase 2, participants who were on 1FED in Phase 1 will receive 4FED therapy for 12 weeks, and participants who were on 4FED during Phase 1 will receive swallowed glucocorticoid therapy for 12 weeks. At the end of 12 weeks of therapy, esophageal biopsies from participant's standard of care (i.e. normal, routine care) endoscopy will be evaluated to determine disease status.
AIM: During liver transplantation, both hospital-acquired (HA) and community-acquired (CA) intra-abdominal infections (IAIs) are involved causing life-threatening diseases. Therefore, comparative studies of aerobic and facultative anaerobic HA-IAIs and CA-IAIs after liver transplantation surgery are necessary.
METHODS AND RESULTS: The species of detected isolates (310) from intra-abdominal fluid were identified and classified into hospital-acquired intra-abdominal infections (HA-IAIs) and community-acquired intra-abdominal infections (CA-IAIs). Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii were the most commonly detected species. The resistant phenotypes were commonly detected among the HA-IAIs; however, the virulent phenotypes were the predominant strains of CA-IAIs. Regrettably, the resistance profiles were shocking, indicating the inefficacy of monotherapy in treating these isolates. Therefore, we confirmed the use of empirical combination therapies of amikacin and meropenem for treating all IAIs (FICI ≤ 0.5). Unfortunately, the high diversity and low clonality of all identified HA and CA-IAIs were announced with D-value in the range of 0.992-1.
CONCLUSION: This diversity proves that there are infinite numbers of infection sources inside and outside healthcare centers.
The intention relates to a medicine for treating a cancer and a preparation method thereof. The medicine comprises the following components in portion: 350 to 400 portions of yeast juice, 40 to 60 portions of white sugar, 3 to 6 portions of yam, 3 to 5 portions of bupleurum, 2 to 4 portions of ginseng, 1 to 4 portions of nelumbonucifera, 1 to 2 portions of licorice, 1 to 2 portions of semen plantaginis, 1 to 2 portions of cassia nomame root, 1 to 2 portions of mantis egg-case, 1 to 2 portions of grains of paradise and 50 to 70 portions of eggs. The preparation method comprises the following steps: grinding and mixing; fermentation for 68 to 72 hours in presence of high-activity dry yeast; fermentation for 72 to 96 hours after temperature reduction; standing, settlement and filtration in an environment with a temperature of 2 DEG C after fermentation; boiling a filtrate for 2 to 3 hours to obtain a condensed decoction; and pelleting and packing to obtain the finished medicine. The medicine is prepared from traditional Chinese medical herbs extremely good to body health, and has functions of promoting qi, clearing heat, diuresis, eliminating stasis, relieving pains and tonifying kidney. Particularly, the medicine has outstanding prevention and curative effect on various malignant tumors. In addition, the medicine produces excellent mouthfeel for drinking and overcomes the drawback that the prior Chinese herbal medicine is too bitter to drink.
FIELD: medicine. SUBSTANCE: described are frothy tablets or granules comprising skeleton material, acid carbonization component, sweetening agent and also macro- and microelements, and optionally vitamins as active ingredients. Frothy tablets and granules contain 20-50 wt % of mannite as skeleton material, 8-25 wt % of potassium hydrocarbonate as main carbonization component, 9-27 wt % of acid as malic acid carbonization component and 0.4-2.2 wt % of aspartam as sweetening agent. Also described is method of preparing such frothy tablets or granules. EFFECT: higher chemical stability and readily pressed tablets or granules. 3 cl, 5 ex, 3 tbl
1. A method of preparing a veterinary composition comprising a water-insoluble active compound suitable for administering to a target animal through a water distribution system, comprising mixing the active compound with a water-immiscible liquid in such a manner that the mixture of active compound and water-immiscible liquid has a density between 0.85 and 1.2, and suspending said mixture in an aqueous carrier. 2. A method according to claim 1, in which said active compound comprises one or more anthelmintics. 3. A method according to claim 2, in which said anthelmintics comprise a benzimidazole or a pro-benzimidazole. 4. A method according to claim 3, in which said anthelmintics is flubendazole. 5. A method according to any one of claims 1-4, in which the active compound and the water-immiscible liquid are used in a weight ratio between 10: 90 and 75: 25. 6. A method according to any one of claims 1-5, in which either the active compound or the water-immiscible liquid has a lower density than water and the other has a higher density than water. 7. A method according to any one of claims 1-6, in which said mixture or the suspension thereof in the aqueous carrier comprises one or more stabilising agents belonging to the group of emulsifiers, surfactants, thickeners, anti-oxidants and antimicrobials. 8. A method according to any one of claims 1-7, in which said water-immiscible liquid is a vegetable oil. 9. A method according to any one of claims 1-8, in which the average particle size of the active compound is between 1 and 30 mkm. 10. A suspoemulsion suitable, optionally after dilution, for administering a veterinarily active compound to a target animal through a water distribution system, comprising a homogeneous suspension in water of a mixture of the active compound and a water immiscible liquid, said mixture having a density between 0.85 and 1.2. 11. A suspoemulsion according to claim 9, comprising one or more of the following features: a) the active compound and the water-immiscible liquid are used in a weight ratio between 10: 90 and 75: 25; b) the active compound is a benzimidazole anthelmintic; c) the water-immiscible liquid is a vegetable oil; d) the suspoemulsion comprises one or more stabilising agents selected from emulsifiers, surfactants, thickeners, anti-oxidants and anti-microbials; e) the weight ratio between said mixture of active compound a water-immiscible liquid and said water is between 80: 20 and 10: 90; f) the density of the mixture of active compound and water-immiscible liquid is between 0.95 and 1.05. 12. A suspoemulsion according to claim 11, in which said benzimidazole anthelmintics is selected from the group of flubendazole, fenbendazole, mebendazole, oxfendazole, albendazole, cambendazole, parbendazole, oxibendazole and cyclobendazole. 13. A suspoemulsion according to claim 12, in which said benzimidazole anthelmintics is flubendazole.
PURPOSE: To provide a skin-beautifying agent which has actions for improving the moisture and firmness of the skin and for preventing and improving the roughness and fine wrinkles of the skin, when orally taken. CONSTITUTION: The skin-beautifying agent contains N-acetyl glucosamine as an active ingredient. The form of the agent is preferably tablets, capsules, powder, granules or liquids. The beautiful skin-stimulating agent may be added to foods such as confections, powdered soups or drinks. When the beautiful skin-stimulating agent is orally administered, the N-acetylglucosamine is quickly absorbed and partially used as a raw material for acidic mucopolysaccharides such as hyaluronic acid or chondroitin sulfuric acid. Thereby, the moisture and firmness of the skin can be improved, and the roughness, fine wrinkles, and so on, of the skin can be prevented and improved.
Ethiopia's healthcare system relies on traditional medicinal practices that use medicinal plants to treat human and livestock ailments. However, the lack of empirical validation regarding the efficacy of these treatments against specific infectious diseases necessitates rigorous scientific investigations. The objective of this study was to investigate the antibacterial activity and phytochemical screening on five selected medicinal plant species, namely Solanum somalense Franchet., Verbascum sinaiticum Benth., Rumex nervosus Vahl, Withania somnifera (L.) Dunal and Calpurnia aurea (Ait.) Benth. The plants were first identified jointly with local informants and later considering mainly their high informant consensus and fidelity level values for their efficacy in treating infectious diseases in the area. Ethanol and aqueous extracts were prepared from the plant materials, and their antibacterial activities were evaluated against standard bacterial strains, representing both gram-positive and gram-negative types. To assess the antibacterial activity of the extracts, the minimum inhibitory concentration (MIC) was determined using the broth dilution method. Additionally, phytochemical screening was performed using standard qualitative tests to identify various secondary metabolites. The results indicated antibacterial efficacy in the ethanol extracts of S. somalense, W. somnifera, and C. aurea against particular bacterial strains (S. somalense against S. agalactiae with MIC of 1.5 mg/mL; W. somnifera against S. aureus and E. coli, with MIC of 2 mg/mL; C. aurea against E. coli and K. pneumoniae, with MICs of 3 mg/mL and 3.5 mg/mL, respectively). The results of the phytochemical screening indicated the presence of steroids, alkaloids, flavonoids, saponins, and terpenoids. The selected medicinal plants demonstrated promising antibacterial activity against certain bacterial strains. The current findings support the long-standing claim of the traditional medical system of the study area for their continued use of these plants in their treatment of infectious diseases. Further investigation is required to isolate the responsible active compounds and characterize the constituents and description of their antibacterial effect for possible use in areas where these infectious diseases are major health problems.
The incidence of head and neck cancers is the 6th in Taiwan, and head and neck cancers are the 5th leading cause of cancer death, causing approximately 2000 death in 2010. Head and neck cancers patients usually require multimodality treatments, including surgery, chemotherapy and radiotherapy. These treatments can cause functional deterioration and worsened quality of life during or after the treatment, and bring tremendous effects on patient's life. When radiotherapy is indicated, it requires 6 to 7 weeks treatment, and most patients suffered from different degrees of mucositis, dermatitis, xerostomia and neck and shoulder tightness during radiotherapy. How to improve quality of life for these patients during radiotherapy is an important task.

Qigong is a mind-body exercise or therapy; it can improve quality of life, such as fatigue, sleep dysfunction and depression through regulation of breath and simple physical exercise. Some found that the qigong can decrease inflammation and show some impact on accommodation of ANS in cancer patients. Most studies focus on how qigong effect on cancer survivors, however, this study is aimed to observe how a six week qigong program influence patients with head and neck cancer during active radiotherapy treatment course. The quality of life, sleep dysfunction or depression and shoulder and neck function will be accessed by questionnaire, and ANS function will be objectively investigated using heart rate variability measurement.
The invention belongs to the technical field of biological medicines, and relates to application of PRPF6 in treatment of prostate cancer and castration-resistant prostate cancer. Application of PRPF6 targeted inhibitor in preparing medicine and pharmaceutical composition for preventing or treating prostate cancer and castration-resistant prostate cancer. The invention discovers for the first time that PRPF6 can promote the progress of prostate cancer and castration-resistant prostate cancer, PRPF6 has higher expression in prostate cancer tissues with higher malignancy, and PRPF6 is inhibited to obviously inhibit the occurrence and development of prostate cancer and castration-resistant prostate cancer. Effects of PRPF6 on prostate cancer and castration resistant prostate cancer treatment resistance. The potential drug resistance function of PRPF6 in endocrine drugs for treating prostate cancer and castration resistant prostate cancer is found, a PRPF6 small-molecule inhibitor is prepared, siRNA or miRNA is generated by inhibiting PRPF6 transcription is found so as to treat clinical prostate cancer and castration resistant prostate cancer. The invention provides a new idea and a new target point for treating the prostatic cancer and castration-resistant prostatic cancer.
Prostate adenocarcinoma (PRAD) is a prevalent global malignancy which depends more on lipid metabolism for tumor progression compared to other cancer types. Although Stearoyl-coenzyme A desaturase (SCD) is documented to regulate lipid metabolism in multiple cancers, landscape analysis of its implications in PRAD are still missing at present. Here, we conducted an analysis of diverse cancer datasets revealing elevated SCD expression in the PRAD cohort at both mRNA and protein levels. Interestingly, the elevated expression was associated with SCD promoter hypermethylation and genetic alterations, notably the L134V mutation. Integration of comprehensive tumor immunological and genomic data revealed a robust positive correlation between SCD expression levels and the abundance of CD8+ T cells and macrophages. Further analyses identified significant associations between SCD expression and various immune markers in tumor microenvironment. Single-cell transcriptomic profiling unveiled differential SCD expression patterns across distinct cell types within the prostate tumor microenvironment. The Gene Ontology and Kyoto Encyclopedia of Genes and Genome analyses showed that SCD enriched pathways were primarily related to lipid biosynthesis, cholesterol biosynthesis, endoplasmic reticulum membrane functions, and various metabolic pathways. Gene Set Enrichment Analysis highlighted the involvement of elevated SCD expression in crucial cellular processes, including the cell cycle and biosynthesis of cofactors pathways. In functional studies, SCD overexpression promoted the proliferation, metastasis and invasion of prostate cancer cells, whereas downregulation inhibits these processes. This study provides comprehensive insights into the multifaceted roles of SCD in PRAD pathogenesis, underscoring its potential as both a therapeutic target and prognostic biomarker.
Sustained high intensity activity that is often accompanied by sleep and nutrient deprivation is a common characteristic of survival training. Survival training is a requirement in the preparation of pilots, where they learn evasion and survival skills that they may need to avoid capture in a situation in which they have bailed from their plane. The physiological stresses associated with the nature of these operations often results in significant decrements in lean body mass, muscle size and muscle endurance and power. During a sudden evacuation from the aircraft the pilot only takes a small survival bag. There is a limit to what can possibly be put in this bag. However, the ability to provide a dietary supplement specifically targeting muscle may provide an important resource for maintaining muscle mass and performance. Thus, the purpose of this study is to determine the efficacy of 14 days of HMB-FA ingestion on maintaining muscle architecture and muscle performance during 4-days of survival training. In addition, anabolic and catabolic markers of stress, inflammation and muscle damage will be assessed.
As a novel minimally invasive technique,laparoscopic surgery has presently become widely accepted as an alternative treatment for malignant diseases. In the treatment of gastric cancers, it has been reported to be an optionalprocedure with the advantages of less invasiveness,less blood loss, faster postoperative recovery and shorter hospital stay, when compared to open surgery. In general, four or five trocars are required in conventional laparoscopic distal gastrectomy (CLDG), and each port results in abdominal injury, which may lead to port site complications, such as wound infection, dehiscence and small bowel herniation. Hence, it remains challenging to determine whether surgical wounds could be minimized during laparoscopic gastric surgery. The development of reduced-port laparoscopic techniques has been largely due to the appearance of multi-channel ports. A conventional trocar port can only be used for inserting a single instrument. With the advancement of laparoscopic devices, a variety of multi-channel ports have been introduced and used in laparoscopic surgeries. At present, multi-channel ports that have been reported include Uni-X devices (Pnavel Systems, Brooklyn, NY, USA), TriPort devices (Advanced Surgical Concepts,Wicklow, Ireland), SILS devices (Covidien, Norwalk, CT, USA), OctoPort devices (DalimSurgNet, Seoul, Korea) and self-made multichannel devices from medical centers globally. The number of ports located on these multichannel devices varies from two to four. Twoport and three-port devices are more commonly used at present in laparoscopic gastric cancer surgery. In recent years, the use of reduced-port laparoscopic gastrectomy has rapidly increased. Several studies have suggested that, in contrast to conventional laparoscopic gastrectomy (CLG), the reduced-port method has some apparent postoperative benefits in the treatment of gastric cancers, such as shorter hospital stay, less pain, less blood loss and better cosmetic results. Among these studies, most have been about distal gastrectomy. Hence, the application of this technique in total gastrectomy is at present relatively less. As a type of reduced-port technique, Kawamura et al. first used this technique in 2011 to treat early distal gastric cancers, and suggested that dual-port laparoscopic distal gastrectomy (DPLDG) is superior to conventional approaches from the cosmetic standpoint, and has the potential to become a technically acceptable procedure. However, due to the more limited operating space when compared to CLDG, it has been generally considered that DPLDG is more difficult to perform than CLDG. The difficulty of DPLDG is mainly due to insufficient intraoperative traction and exposure, which makes the principle of triangulation and counteraction in DPLDG less good when compared to those in CLDG. In addition, since merely one additional trocar is located at one side of the abdominal wall, it is difficult for the surgeon to change position with the assistant, when necessary. The application of DPLDG to distal gastric cancer remains controversial, and critical comments have been made regarding it.
Fenofibrate Tablet is a lipid regulating agent available as tablets for oral administration. Each tablet contains 48 mg or 145 mg of fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is C20H21O4Cl and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79° to 82°C. Fenofibrate is a white solid which is stable under ordinary conditions.

Inactive Ingredients

Each tablet contains anhydrous lactose, croscarmellose sodium, hypromellose, magnesium stearate, purified water, simethicone emulsion, and sodium lauryl sulfate.
Normal tissue tolerance of the rectum limits the dose of radiation that can be delivered to the prostate for curative treatment of prostate cancer. Amifostine is a radioprotector, an agent that reduces tissue damage incurred by ionizing radiation. It has been well studied in humans and is approved for intravenous use. Rectal administration results in a preferential accumulation of Amifostine in the rectal mucosa, and neither free parent compound nor free active metabolite have been detected in systemic circulation. This trial proposes to observe the rate of early and late bowel toxicity in a group of patients with prostate cancer receiving standard high dose, 3D conformal external beam radiotherapy and concurrent intra-rectal applications of Amifostine. Primary measures of rectal toxicity (RTOG radiation morbidity scoring) will also be compared with self-assessment measures of quality of life, and rectal radiation dose as assessed by dose-volume histograms.
There is provided a sperm extender medium for prolonging the fertility of bovine spermatozoa during liquid storage of the spermatozoa. The medium comprises a monosaccharide energy source for the spermatozoa. The one or more ? or ? amino acid osmolytes are selected from mono-amino carboxylic and mono-amino sulfonic acids, each independently having an R side group selected from the group consisting of H and non-polar, neutral open aliphatic chains excluding branched C3 and longer aliphatic chains. The medium also comprises one or more antioxidants and physiologically acceptable inorganic salts for maintaining sperm viability, and is buffered for maintaining pH in a range of from about 7.0 to about 8.5. Further, in embodiments, the medium has a concentration of sodium ions of less than about 95 mM, and an osmolarity in a range of from about 290 mOsm/L to about 400 mOsm/L. There are also provided preparations comprising the spermatozoa in the medium, methods for preparing the medium and methods for fertilisation of an ovum comprising contacting the ovum with spermatozoa administered in the sperm extender medium.
Approximately 15% cases of colon cancer are associated a type of inherited susceptibility called defective DNA mismatch repair (MMR), which is frequently measured by either the presence of microsatellite instability (MSI) or by testing for loss of the protein products for genes involved in DNA MMR (MLH1, MSH2, MSH6 and PMS2). Tumors are classified according to the percentage of abnormal microsatellite regions present: \>30-40% as high-level MSI (MSI-H), \<30-40% as low-level MSI (MSI-L) and no abnormalities as microsatellite stable (MSS). In the condition of MSI presence, evidence shows that MSI is a marker of a more favorable survival outcome and a predictor of decreased benefit from adjuvant therapy with 5-FU in patients with stage II disease. MSI status can be used in the clinic as a prognostic tool to identify a subgroup of stage II patients with improved prognosis. Patients with MSI-H tumors are not suggested to have adjuvant chemotherapy while patients with MSI-L or MSS tumors can benefit from adjuvant chemotherapy. oral tegafur-uracil as an adjuvant chemotherapy in patients with Dukes' stage B2 and C2 colon cancer could be a good alternative to infusional 5-FU. Current evidences suggest adjuvant 5-FU-based therapy could improve survival outcome for patients with stage II MSI-L or MSS colon cancer, but not for patients with MSI-H colon cancer. Thus, oral tegafur-uracil is considered to have similar efficacy as 5-FU in this population.